Qualigen Therapeutics Changes Auditors to BDO USA
Ticker: AIXC · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1460702
| Field | Detail |
|---|---|
| Company | Qualigen Therapeutics, INC. (AIXC) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, internal-controls
TL;DR
Qualigen swapped auditors from Marcum to BDO; Marcum had flagged internal control issues.
AI Summary
Qualigen Therapeutics, Inc. announced on October 1, 2025, a change in its independent registered public accounting firm. The company dismissed Marcum LLP and has appointed BDO USA, P.A. as its new auditor. This change comes after the previous auditor, Marcum LLP, expressed concerns regarding internal controls over financial reporting in their audit report for the fiscal year ended December 31, 2024.
Why It Matters
A change in auditors can signal potential issues with financial reporting or internal controls, requiring investor scrutiny. The transition to BDO USA, P.A. from Marcum LLP, which had noted control deficiencies, warrants attention.
Risk Assessment
Risk Level: medium — The change in auditor, especially with prior auditor concerns about internal controls, introduces a moderate level of risk regarding financial reporting integrity.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- Marcum LLP (company) — Former Certifying Accountant
- BDO USA, P.A. (company) — New Certifying Accountant
- October 1, 2025 (date) — Effective date of auditor change
- December 31, 2024 (date) — Fiscal year end for previous audit report
FAQ
When did Qualigen Therapeutics, Inc. dismiss Marcum LLP?
Qualigen Therapeutics, Inc. dismissed Marcum LLP effective October 1, 2025.
Who has Qualigen Therapeutics, Inc. appointed as its new independent registered public accounting firm?
Qualigen Therapeutics, Inc. has appointed BDO USA, P.A. as its new independent registered public accounting firm.
Did Marcum LLP consent to the change in auditors?
Yes, Marcum LLP has provided a letter stating they consent to the change.
Were there any disagreements between Qualigen Therapeutics and Marcum LLP?
No, the filing states there were no disagreements or reportable events that would require disclosure.
What was the reason for the change in auditors?
The change was made by the company, and while no disagreements were reported, Marcum LLP's audit report for the fiscal year ended December 31, 2024, did note deficiencies in internal controls over financial reporting.
Filing Stats: 1,989 words · 8 min read · ~7 pages · Grade level 12.2 · Accepted 2025-10-06 20:07:42
Key Financial Figures
- $0.001 — ch registered Common stock (par value $0.001 per share) QLGN The Nasdaq Stock Ma
Filing Documents
- form8-k.htm (8-K) — 57KB
- ex16-1.htm (EX-16.1) — 5KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001493152-25-017162.txt ( ) — 270KB
- qlgn-20251001.xsd (EX-101.SCH) — 3KB
- qlgn-20251001_lab.xml (EX-101.LAB) — 33KB
- qlgn-20251001_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
financial statements for the year ending December 31, 2025
financial statements for the year ending December 31, 2025. The reports of Withum on the Company's consolidated financial statements for the fiscal years ended December 31, 2024 did not contain an adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles, except for the inclusion of an explanatory paragraph regarding the substantial doubt about the Company's ability to continue as a going concern. During the period from July 11, 2024 through the Company's most recent fiscal year ended December 31, 2024, and the subsequent interim period through October 1, 2025, there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or disputes between the Company and Withum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Withum, would have caused Withum to make reference to the subject matter of the disagreements in connection with the reports on the Company's financial statements for such periods. In addition, during the Company's most recent fiscal year ended December 31, 2024 and the subsequent interim period through October 1, 2025, there were no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions), except for material weaknesses in the Company's internal control over financial reporting related to: (i) the lack of sufficient number of personnel within the accounting function to adequately segregate duties, (ii) the lack of designed and implemented effective Information Technology General Controls ("ITGC") related to access controls to financial accounting systems, and (iii) the lack of formalized documentation of its processes and controls that could be evaluated for proper design and implementation. The Company provided Withum with a copy of this Current Report on For
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 6, 2025 QUALIGEN THERAPEUTICS, INC. By: /s/ Kevin A. Richardson II Name: Kevin A. Richardson II Title: Co-Chief Executive Officer